Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.54 |
| ▸ | TK1 | P04183 | 3/20 | 0.51 |
| ▸ | TK2 | O00142 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20360357 | 0.92 | TYMP (0.52) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL15329018 | 0.87 | TYMP (0.55) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL15329291 | 0.86 | TYMP (0.58) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL20608955 | 0.85 | TYMP (0.55) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL6297016 | 0.85 | TK2 (0.55) | TYMPTK2ALDH1A1LMNAALB | |
| SCHEMBL1904388 | 0.85 | TYMP (0.59) | TYMPTK1TK2 | |
| SCHEMBL16620094 | 0.84 | TYMP (0.58) | TYMPTK1TK2 | |
| SCHEMBL15329022 | 0.81 | TYMP (0.52) | TYMPTK1TK2 | |
| SCHEMBL15329026 | 0.80 | TYMP (0.53) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL25358240 | 0.80 | TYMP (0.53) | TYMPTK1TK2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3920884-B1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4707394-A2 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250388900-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2025-12-25 | — | — | US | disclosed |
| US-20250333742-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE | INSITRO, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025226980-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE | INSITRO, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025072748-A2 | COMPOSITIONS AND METHODS FOR TREATING NONALCOHOLIC FATTY LIVER DISEASE | INSITRO, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240336921-A1 | USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-10-10 | — | — | US | disclosed |
| EP-3494123-B1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | ARROWHEAD PHARMACEUTICALS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4367241-A1 | USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2024-05-15 | — | — | EP | disclosed |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | Arrowhead Pharmaceuticals, Inc. | 2019-12-19 | — | — | US | disclosed |
| EP-3573623-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| EP-3568482-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-09-26 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3494123-A2 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018140920-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | Arrowhead Pharmaceuticals Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018132432-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336921-A1 | USE OF OLIGONUCLEOTIDES FOR INDIVIDUALS WITH RENAL IMPAIRMENT | HAVCR2, HNRNPA2B1, HNRNPAB | TYMP 474/4885TK1 759/4885TK2 211/4885 |
| US-20250333742-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE | GCKR, GCK, PCK1 | TYMP 1756/4885TK1 214/4885TK2 123/4885 |
| US-20250388900-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F13B, F13A1, F12 | TYMP 4534/4885TK1 4457/4885TK2 4253/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | TYMP 2205/4885TK1 434/4885TK2 1010/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | TYMP 2205/4885TK1 434/4885TK2 1010/4885 |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | HAVCR2, ASGR1, HDGF | TYMP 2276/4885TK1 454/4885TK2 901/4885 |
| US-20190382763-A1 | Compositions and Methods for Inhibition of Factor XII Gene Expression | F12, F13A1, F13B | TYMP 4454/4885TK1 3721/4885TK2 4215/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | TYMP 2276/4885TK1 454/4885TK2 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.